Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06392932 · ClinicalTrials.gov registry record · NA
Esophageal Temperature During PVI Using Q-DOT Micro
A NA study of Atrial Fibrillation Paroxysmal, sponsored by Cedars-Sinai Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06392932 is a NA study of Atrial Fibrillation Paroxysmal that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 30 participants, below the 182-participant average among 4 other Atrial Fibrillation Paroxysmal trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06392932, a NA study of Atrial Fibrillation Paroxysmal, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess how two different ablation strategies, using two different ablation catheters during catheter ablation for paroxysmal atrial fibrillation, affect the temperature of the esophagus during ablation, and the risk of injury to the esophagus.
Conditions Studied
Interventions
- DEVICE QDOT Micro ablation catheter
- DEVICE ST SF ablation catheter
Study Locations (1)
California
- Cedars-Sinai Smidt Heart Institute - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-10-04 |
| Est. Completion | 2027-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06392932
The ClinicalTrials.gov registry entry for NCT06392932 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 4 other Atrial Fibrillation Paroxysmal trials with a reported enrollment target (84% lower). The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atrial Fibrillation Paroxysmal appearing as the primary indexed condition, and to 2 interventions - of which QDOT Micro ablation catheter is the first listed.
NCT06392932 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06392932 about?
NCT06392932 is a clinical study titled "Esophageal Temperature During PVI Using Q-DOT Micro". This study will assess how two different ablation strategies, using two different ablation catheters during catheter ablation for paroxysmal atrial fibrillation, affect the temperature of the esophagus during ablation, and the risk of injury to the esophagus.
What is the current status of trial NCT06392932?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-10-04. Estimated completion is 2027-03.
What conditions does trial NCT06392932 study?
This clinical trial studies the following conditions: Atrial Fibrillation Paroxysmal.
What interventions are being tested in trial NCT06392932?
The interventions under investigation include: QDOT Micro ablation catheter (DEVICE), ST SF ablation catheter (DEVICE).
Who is sponsoring clinical trial NCT06392932?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06392932 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation Paroxysmal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Full-Avoidance vs. Permissive/Regulated Drinking & Outcomes On Fibrillation
RECRUITING · NA
-
RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.
ACTIVE NOT RECRUITING · NA
-
RiLuzole to Reduce Atrial FIb Study Using Holter Monitoring
RECRUITING · Phase 2
-
Assert-IQ Implantable Cardiac Monitor (ICM) Post Market Study
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.